UNSPSC 51291710: Bipenamol hydrochloride

This classification denotes an antidepressant agent with the molecular formula C14H15NOS.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 65FL7UEP0F. The term bipenamol hydrochloride is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule bipenamol hydrochloride under HS 29309085 and SITC 51549. As of Q4 2014, BIPENAMOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(C(C1)CN)SC2CCCCC2CO.CL.

UNSPSC 51291710 Bipenamol hydrochloride is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities posted under this code solicitate naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through cooperative purchasing — none of which are bipenamol hydrochloride. The mismatch suggests tagging inconsistency rather than active market demand for the specific pharmaceutical named in the code.

State and local bodies issuing under this code span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Recent solicitations originate from Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serving multiple states including Oregon. The Seminole County procurement (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to Sanford, Florida. The MMCAP RFP (S1070000015802, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products distributed across state and local government facilities, requiring manufacturer compliance with cGMP, DSCSA, and FDA requirements, with pricing evaluated on a 75-percent weight. The Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription fulfillment models outside traditional PBM and GPO channels. Recent activity concentrates in Florida and Texas with multistate cooperative purchasing vehicles, but bipenamol hydrochloride itself does not appear in the posted solicitations.